{"id":22524,"date":"2025-11-01T17:21:12","date_gmt":"2025-11-01T17:21:12","guid":{"rendered":"https:\/\/tezgyan.com\/index.php\/2025\/11\/01\/dr-reddys-shares-slide-6-after-canada-flags-semaglutide-compliance-issue-markets-news\/"},"modified":"2025-11-01T17:21:12","modified_gmt":"2025-11-01T17:21:12","slug":"dr-reddys-shares-slide-6-after-canada-flags-semaglutide-compliance-issue-markets-news","status":"publish","type":"post","link":"https:\/\/tezgyan.com\/index.php\/2025\/11\/01\/dr-reddys-shares-slide-6-after-canada-flags-semaglutide-compliance-issue-markets-news\/","title":{"rendered":"Dr Reddy\u2019s Shares Slide 6% After Canada Flags Semaglutide Compliance Issue | Markets News"},"content":{"rendered":"


\n<\/p>\n

\n

Last Updated:<\/span>

Shares of Dr Reddy’s hit a five-month low as analysts said that the recent development can delay the launch of its new injection<\/h2>\n
<\/p>\n
\n
\n
\n
\"font\"<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\"Dr<\/p>\n

Dr Reddy’s Share Price<\/p>\n<\/figure>\n<\/div>\n

Dr Reddy\u2019s Share Price:<\/strong> Shares of Dr Reddy\u2019s Laboratories slipped to Rs 1,180.90 apiece in early trade, the lowest level in over five months, making it the top loser on the Nifty Pharma index, which was down 0.7 percent.<\/p>\n

The decline came after the company disclosed in an exchange filing that it received a non-compliance notice from Canadian authorities related to its Abbreviated New Drug Submission (ANDS) for Semaglutide injection. The notice seeks additional information and clarifications on specific parts of the submission.<\/p>\n

Dr Reddy\u2019s said it will respond promptly within the stipulated timeframe. \u201cWe remain confident in the quality, safety and comparability of our proposed product and are committed to bringing this important therapy to patients in Canada and other markets at the earliest,” the company said, adding that it will provide further updates when necessary.<\/p>\n

What analysts say<\/h3>\n

Analysts cautioned that the regulatory setback could delay the planned launch of Dr Reddy\u2019s Semaglutide injection \u2014 the active ingredient in Novo Nordisk\u2019s blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.<\/p>\n

JP Morgan noted that the development could push back Dr Reddy\u2019s anticipated first-to-market launch from January 2026, weakening its first-mover advantage. The brokerage estimates that the delay could put at risk roughly $30 million in potential FY26 revenue and nearly $100 million in FY27 revenue from the Canadian Semaglutide opportunity.<\/p>\n

Emkay Global expects a six-month delay in the product launch.<\/p>\n

Shares of Shaily Engineering Plastics fell over 17 percent to Rs 2,115 after the news. According to its FY25 annual report, Dr Reddy\u2019s is among its major clients in the pharmaceutical segment.<\/p>\n

Dr Reddy\u2019s Q2 results<\/h3>\n

On October 24, Dr Reddy\u2019s reported a 7 percent year-on-year rise in consolidated net profit to Rs 1,347.1 crore for Q2 FY26, below brokerage estimates of Rs 1,450 crore.<\/p>\n

The company\u2019s profit was weighed down by intense competition for the generic version of cancer drug Revlimid in North America.<\/p>\n

Revenue from operations rose nearly 10 percent year-on-year to Rs 8,828 crore, exceeding expectations of around Rs 8,700 crore and higher than Rs 8,038 crore reported in the year-ago period.<\/p>\n

\n
\n
<\/p>\n
\"Aparna<\/figure>\n

<\/span><\/p>\n

Aparna Deb<\/a><\/p>\n

Aparna Deb is a Subeditor and writes for the business vertical of News18.com. She has a nose for news that matters. She is inquisitive and curious about things. Among other things, financial markets, economy, a…Read More<\/span><\/p>\n<\/div>\n<\/div>\n

Aparna Deb is a Subeditor and writes for the business vertical of News18.com. She has a nose for news that matters. She is inquisitive and curious about things. Among other things, financial markets, economy, a… Read More<\/span><\/p>\n<\/div>\n<\/div>\n

Follow News18 on Google<\/a>. Join the fun, play QIK games on News18<\/a>. Stay updated with all the latest business news, including market trends<\/a>,\u00a0stock updates<\/a>,\u00a0tax<\/a>, IPO,\u00a0banking finance<\/a>, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also Download the\u00a0News18 App<\/a> to stay updated.<\/span><\/div>\n
First Published:<\/span><\/p>\n
\n

October 30, 2025, 12:28 IST<\/p>\n<\/div>\n<\/div>\n

News<\/a> business<\/a> markets<\/a> Dr Reddy\u2019s Shares Slide 6% After Canada Flags Semaglutide Compliance Issue<\/span><\/div>\n
\n
\n
Disclaimer: Comments reflect users\u2019 views, not News18\u2019s. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use<\/a> and Privacy Policy<\/a>.<\/div>\n<\/div>\n<\/div>\n

Read More<\/span><\/p>\n<\/div>\n


\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Last Updated:October 30, 2025, 12:28 IST Shares of Dr Reddy’s hit a five-month low as analysts said that the recent development can delay the launch of its new injection Dr Reddy’s Share Price Dr Reddy\u2019s Share Price: Shares of Dr Reddy\u2019s Laboratories slipped to Rs 1,180.90 apiece in early trade, the lowest level in over…<\/p>\n","protected":false},"author":1,"featured_media":22525,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[],"class_list":["post-22524","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"_links":{"self":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts\/22524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/comments?post=22524"}],"version-history":[{"count":0,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts\/22524\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/media\/22525"}],"wp:attachment":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/media?parent=22524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/categories?post=22524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/tags?post=22524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}